Neoplasms

Blood and Lymph Conditions

All Conditions

Nervous System Diseases

Skin and Connective Tissue Diseases

Rare Diseases

Leukemia

Sarcoma

Osteosarcoma

Central Nervous System Neoplasms

Neuroblastoma

Sarcoma, Ewing

Nervous System Neoplasms

Rhabdomyosarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Neuroectodermal Tumors, Primitive, Peripheral

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Neuroepithelial

Neoplasms, Germ Cell and Embryonal

Neoplasms, Glandular and Epithelial

Neoplasms, Nerve Tissue

Neoplasms, Bone Tissue

Neoplasms, Connective Tissue

Myosarcoma

Soft Tissue Sarcoma

Ewing Sarcoma

Neuroepithelioma

Cohort 1 : High risk Neuroblastoma, High risk Rhabdomyosarcoma, High risk Ewing Sarcoma Family Tumor, High risk Osteosarcoma, High risk Leukaemia (secondary acute myeloid leukaemia or biphenotypic acute leukaemia) Cohort 2 : Extracerebral and cerebral high risk tumor, High risk Leukaemia (leukaemia with high MRD) Sampling on blood, bone marrow and cerebrospinal fluid

Cohort 3 : Intermediate or low risk tumors : Neuroblastoma, Rhabdomyosarcoma, Ewing Sarcoma Family Tumor, Osteosarcoma Sampling on blood, bone marrow and cerebrospinal fluid

biological sampling during treatment and follow-up

Sampling on blood, bone marrow and cerebrospinal fluid

Gudrun SCHLEIERMACHER, MD

Cécile Simondi

Catherine DEVOLDERE, MD

Isabelle PELLIER, MD

Sebastien KLEIN, MD

Stéphane DUCASSOU, MD

Liana-Stéphania CARAUSU, MD

Marianna DEPARIS, MD

Justyna KANOLD, MD

Claire BRIANDET, MD

Cécile PERRET, MD

Anne-Sophie DEFACHELLESTHOMASSIN, MD

Christophe PIGUET, MD

Nadège CORRADINI, MD

Yves BERTRAND, MD

Carole COZE, MD

Laure SAUMET, MD

Estelle THEBAUD, MD

Pierre-Simon ROHRLICH, MD

Arnaud PETIT, MD

André BARUCHEL, MD

Frédéric MILLOT, MD

Claire PLUCHART, MD

Sophie TAQUE, MD

Pascale SCHNEIDER, MD

Claire Berger, MD

Catherine PAILLARD, MD

Marion GAMBART, MD

Pascale BLOUIN, MD

Pascal CHASTAGNER, MD

Claudia PASQUALINI, MD

Methodology:

Prospective, multicentric, open, non-randomised, non-therapeutic, interventional study

To identify and characterise:

* meaningful molecular genetic alterations,
* meaningful immunological features of high risk childhood, adolescents and young adult cancers, at diagnosis, during patient treatment and follow-up (time dimension).

Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO)

Molecular and Immunological Characterisation of High Risk CHildhood Cancer At DiagnOsis, Treatment and Follow-up - Biological Evaluation in Children, Adolescents and Young Adults -

Identification of molecular genetic alterations based on molecular characterisation of tumor at diagnosis, during patient treatment and follow-up (time dimension)

Identification and characterisation of the tumor microenvironment and the host's immunological profile, at diagnosis and during patient treatment

Comparison between genetic variations identified at diagnosis and those identified on circulating tumor DNA during treatment, FU and/or relapse

To characterise biomarkers, based on molecular analyses of tumour samples from diagnosis, for prognostic and predictive purposes.

To characterise the tumour microenvironment and the host's immunological profile, for prognostic and predictive purposes.

To identify potential prognostic and predictive biomarkers on samples collected during patient's treatment and follow-up, based on changes on circulating tumour DNA (ctDNA), detected by molecular biology techniques, and on immunological findings

To compare molecular and immunological findings at diagnosis and during treatment (data integration)

To investigate the impact of the tumour microenvironment and host's immunological profile on the disease staging at diagnosis, by comparing patients with metastatic to patients with localised disease

Institut Curie

Spots Global Cancer Trial Database for sampling on blood, bone marrow and cerebrospinal fluid